Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).
about
Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation.Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses.Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination.Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria.Has Wild Poliovirus Been Eliminated from Nigeria?Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmissionAn economic analysis of poliovirus risk management policy options for 2013-2052Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needsCharacterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation.Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria.Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy.The potential impact of expanding target age groups for polio immunization campaigns.Preeradication vaccine policy options for poliovirus infection and disease control.National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication.Vaccine-derived polioviruses.Polio endgame: the global introduction of inactivated polio vaccine.Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication.Addressing the Challenges and Opportunities of the Polio Endgame: Lessons for the Future.Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines-Lessons Learned From the Global Perspective.The Evolutionary Pathway to Virulence of an RNA Virus.The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management.Dynamics affecting the risk of silent circulation when oral polio vaccination is stopped.Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in northern India.Poliovirus vaccination during the endgame: insights from integrated modeling.Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes.Lessons From the Polio Endgame: Overcoming the Failure to Vaccinate and the Role of Subpopulations in Maintaining Transmission.Immune Serum From Sabin Inactivated Poliovirus Vaccine Immunization Neutralizes Multiple Individual Wild and Vaccine-Derived Polioviruses.Polio endgame: the global switch from tOPV to bOPV.Applying the Concept of Peptide Uniqueness to Anti-Polio Vaccination.Modeling options to manage type 1 wild poliovirus imported into Israel in 2013.The risk of type 2 oral polio vaccine use in post-cessation outbreak response.Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.Modeling the dynamics of oral poliovirus vaccine cessation.Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria.Genetic analysis of poliovirus strains isolated from sewage in Poland.Modelling Risk to US Military Populations from Stopping Blanket Mandatory Polio Vaccination.Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations.
P2860
Q33873406-A4231524-CF45-468A-B594-104B145839E1Q34632088-FAC4E05C-89BB-410D-9DF5-4177BE27278EQ35131980-D296E1EC-35E2-4611-87B0-1815BB95F4A5Q35662053-B429FFA9-2D2D-422A-A417-AA5C65C381AFQ35758622-3D3E824E-DF1F-493F-AE58-1763E4552E41Q35779660-42151C4F-C698-4296-9E28-8CC7B1DC23FDQ35779856-64899CBB-2A06-4C03-A557-B5788C8947D1Q35787304-BFE86CA2-9DDA-4981-A7E6-891BF3E9203BQ35787331-635938BC-4786-4CAC-A42D-B574C6F4CC7EQ35968325-56ABC393-F81C-4B86-8D06-383438D55C66Q36031421-20B3EF8C-1E27-4AB0-B942-EB6AB553CA8BQ36035498-72996589-8EC0-48F7-9CDE-137EAE499590Q36433974-761A9680-7C84-4FEA-956C-21717C76E540Q37542082-A79006D9-17B2-4138-9E40-03CB84304EA0Q37568832-644F37C8-5E8A-4286-8DB1-EB6D006A3D50Q38086593-E8EFEB33-DC5A-4920-9AC7-E5A9FF9B3619Q38168905-DF8BA008-4876-4511-B9B5-7A16D9614841Q38260375-87D9B8C0-C6D7-4193-8DB3-10A5361E6EDEQ38322526-0ACB8FF4-78BD-4BA6-8539-37C4A7CBF5BBQ38323836-5C75568B-F3E1-41D2-A0FD-68F07F477226Q38637663-A9BE0BCA-7EF5-4AB1-B112-43980EA36354Q38637670-4D67B6A0-A72E-47E7-9ADF-75A426A62066Q38740160-0D918E24-9EF8-4884-81BF-C3E82515F44AQ38796753-2A1DFD51-F0AD-4A93-9719-FD2776BF3A66Q38914168-D3014D41-94B2-4B59-BA3A-3680FC6147F2Q39112948-1ED00A3D-AA55-4BAA-8E33-782F06022C6FQ39258694-93D73834-5235-48E2-A6A3-9ACD7BF2A1AFQ40071746-53452EA2-3787-48C4-99FA-B3D9B5C43FF1Q40071754-6303E6A7-4585-4103-9E55-45B6508DCC4BQ40238369-4AD93CEB-D2C0-4ED6-9D8E-DCC7709D4D89Q40838379-D5F72407-33C2-4901-B869-E64D0A2B14ECQ41122240-06483663-C42E-4804-BFEE-938C3F9B14DEQ41692843-65076E0E-D407-4FD6-B05D-58C380BE7F8DQ41925239-7F6CCFA5-9FA0-4370-9B3C-F31E979E81E2Q42183578-9A8A6758-5D72-43DF-B2C4-B8DB43B2AD9BQ42183580-22BD76DB-BC19-4C86-818D-C84C0A7FE6DEQ42183582-41E70303-08C4-4984-8CF8-C3C7259D9D79Q42262657-6C49A67D-9121-4BB2-A534-D4887377CBC8Q43373067-5957B7AD-AE91-4EFB-B8A1-33E65EB3EA74Q47556747-52CA27C6-CAB0-47D8-A571-4E1B6E600BE9
P2860
Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Oral poliovirus vaccine evolut ...... derived polioviruses (cVDPVs).
@en
type
label
Oral poliovirus vaccine evolut ...... derived polioviruses (cVDPVs).
@en
prefLabel
Oral poliovirus vaccine evolut ...... derived polioviruses (cVDPVs).
@en
P2093
P2860
P50
P356
P1433
P1476
Oral poliovirus vaccine evolut ...... derived polioviruses (cVDPVs).
@en
P2093
Jong-Hoon Kim
Kimberly M Thompson
M Steven Oberste
Olen M Kew
Ousmane M Diop
Stephen L Cochi
Steven G F Wassilak
P2860
P304
P356
10.1111/RISA.12022
P577
2013-03-07T00:00:00Z